Technical Analysis for XLO - Xilio Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Support | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| NR7 | Range Contraction | -7.73% | |
| Narrow Range Bar | Range Contraction | -7.73% | |
| Inside Day | Range Contraction | -7.73% | |
| Wide Bands | Range Expansion | -7.73% | |
| Gapped Up | Strength | -7.73% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -3.20% | |
| Inside Day | Range Contraction | -3.20% | |
| Wide Bands | Range Expansion | -3.20% |
| Alert | Time |
|---|---|
| 200 DMA Support | about 21 hours ago |
| 60 Minute Opening Range Breakdown | about 21 hours ago |
| 3x Volume Pace | about 21 hours ago |
| Down 5% | about 21 hours ago |
| Fell Below 200 DMA | about 21 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 06/13/2024
Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune system for cancer patients. Its checkpoint inhibitor programs include XTX101, is a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1 clinical trials in patients with solid tumors; and cytokine programs comprise XTX202, XTX301, and XTX401, which are modified form of IL-2 that is masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Tumor Cancer Immunotherapy Immunotherapies Immune Checkpoint Checkpoint Inhibitor Tumor Microenvironment
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Tumor Cancer Immunotherapy Immunotherapies Immune Checkpoint Checkpoint Inhibitor Tumor Microenvironment
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.93 |
| 52 Week Low | 0.49 |
| Average Volume | 272,020 |
| 200-Day Moving Average | 0.93 |
| 50-Day Moving Average | 0.91 |
| 20-Day Moving Average | 1.10 |
| 10-Day Moving Average | 1.01 |
| Average True Range | 0.14 |
| RSI (14) | 46.24 |
| ADX | 25.43 |
| +DI | 18.47 |
| -DI | 24.54 |
| Chandelier Exit (Long, 3 ATRs) | 1.12 |
| Chandelier Exit (Short, 3 ATRs) | 1.20 |
| Upper Bollinger Bands | 1.42 |
| Lower Bollinger Band | 0.78 |
| Percent B (%b) | 0.25 |
| BandWidth | 58.25 |
| MACD Line | 0.02 |
| MACD Signal Line | 0.05 |
| MACD Histogram | -0.0333 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.05 | ||||
| Resistance 3 (R3) | 1.06 | 1.03 | 1.03 | ||
| Resistance 2 (R2) | 1.03 | 1.00 | 1.03 | 1.03 | |
| Resistance 1 (R1) | 0.99 | 0.98 | 0.97 | 0.98 | 1.02 |
| Pivot Point | 0.96 | 0.96 | 0.95 | 0.95 | 0.96 |
| Support 1 (S1) | 0.91 | 0.93 | 0.90 | 0.90 | 0.86 |
| Support 2 (S2) | 0.88 | 0.91 | 0.88 | 0.85 | |
| Support 3 (S3) | 0.84 | 0.88 | 0.85 | ||
| Support 4 (S4) | 0.83 |
